Product Development and Innovation - Evolve Rat, launched in January 2024, is the primary revenue-generating product, utilizing cottonseed oil to reduce fertility in rats[25]. - Evolve Mouse was introduced in May 2024, targeting mouse populations with similar technology as Evolve Rat, and is authorized for sale in 37 states[27]. - ContraPest is registered in all 50 states and is the first EPA-registered liquid contraceptive bait for rodent control, aligning with the EPA's push for non-lethal alternatives[41]. - Evolve Rat is exempt from federal registration due to its classification as a minimum risk pesticide, allowing for broader marketability[26]. - The company is focusing on ongoing product innovation and regulatory approvals for ContraPest and Evolve, both in the U.S. and globally[51]. - The company has filed a U.S. utility patent application for Evolve, which, if issued, would provide protection through 2044[76]. - Evolve meets EPA requirements as a minimum risk product, exempting it from federal registration[67]. Market and Sales Performance - The company is exploring international markets for Evolve products through distributors[28]. - Evolve is authorized for sale in 48 states and territories, while ContraPest is registered in all 50 states and the District of Columbia[84]. - The company has demonstrated over 90% reduction in rat populations through its fertility control products when integrated into an Integrated Pest Management (IPM) strategy[61]. - Revenues for the year ended December 31, 2025, were $2.2 million, a 20% increase from $1.9 million in 2024, driven primarily by the Evolve product line, which accounted for 81% of total revenue[183]. - Gross profit for 2025 was $1.4 million, resulting in a gross profit margin of 62.5%, up from $1.0 million and a 54.1% margin in 2024, attributed to the favorable mix of Evolve products[185]. - Evolve products, launched in January 2024, significantly contributed to revenue growth, with sales increasing across all major distribution channels, including e-commerce and retail[178]. Financial Performance and Challenges - The company reported net losses of $6.4 million and $6.2 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $142.5 million as of December 31, 2025[138]. - The company has incurred significant operating losses every quarter since inception and anticipates continuing to incur substantial losses in the future[138]. - The company expects to incur substantial and increased expenses as it continues to develop and market its proprietary products and product candidates[139]. - The company may face unforeseen expenses and complications that could adversely affect its financial condition and ability to achieve market acceptance for its products[140]. - The company's recurring losses from operations and negative cash flows raised substantial doubt about its ability to continue as a going concern, which was alleviated by successful equity raises during the year[219]. Operational Risks and Regulatory Environment - Regulatory changes by the EPA may shift market preferences towards non-lethal solutions, impacting traditional rodenticide use[45]. - Regulatory approval processes for product candidates are lengthy and unpredictable, and failure to obtain such approvals could jeopardize the company's business[97]. - The company is currently facing economic uncertainty, which may adversely affect customer spending and revenue due to inflation and geopolitical instability[95]. - The potential for increased tax liabilities due to changing regulations could adversely affect the company's results of operations[96]. - The company may need to seek strategic partners for manufacturing and distribution earlier than desired, potentially on less favorable terms[93]. Human Resources and Management - The company has 23 full-time employees, with 11 engaged in manufacturing, quality assurance, and R&D[74]. - The company currently has 23 full-time employees and one part-time employee, indicating a need for additional personnel to support future growth[113]. - The board of directors oversees the company's cybersecurity risk management framework, ensuring alignment with overall business objectives[163]. Cybersecurity and Legal Risks - The company is subject to various cybersecurity risks that could negatively impact its reputation and business operations[136]. - The company has implemented various cybersecurity measures to manage risks to its information systems and data[159]. - The company faces risks related to legal proceedings that could result in significant harm to its financial condition and operating results[128]. Financing and Capital Structure - The company plans to finance its cash needs primarily through the sale of equity securities and debt financings, with no committed external funding currently available[143]. - Future financing efforts may present challenges, potentially affecting stockholder rights and causing stock price declines due to dilution[144]. - Cash and cash equivalents at the end of 2025 were $7.6 million, a significant increase from $1.3 million at the end of 2024, bolstered by $13.2 million in net proceeds from equity transactions[191]. - The company has never declared or paid cash dividends on its common stock and intends to retain all available funds for operations and growth[173]. Inventory and Asset Management - Inventory is valued at the lower of cost or net realizable value, with quarterly evaluations to determine any necessary write-downs for obsolete or excess inventory[204]. - The company had property and equipment purchases of $84,000 in 2024, offset by proceeds of $28,000 from the sale of certain equipment[201]. - In 2025, cash used in investing activities included purchases of held-to-maturity investments of $3.0 million and property and equipment purchases of $138,000, with maturities of held-to-maturity investments at $2.0 million[201].

Financial Performance - Net operating revenue for Q4 2025 was $138.0 million, remaining constant compared to Q4 2024, while full-year revenue was $573.0 million, a decrease of 1%[6] - Earnings from operations increased by 117% to $10.4 million in Q4 2025, and by 331% to $51.3 million for the full year[6] - Adjusted EBITDAR for Q4 2025 was $23.9 million, an increase of 13%, and for the full year, it was $105.4 million, an increase of 3%[6] - The company reported a basic net loss per share of ($0.61) for Q4 2025, a 79% improvement from ($2.94) in Q4 2024[8] - The net loss attributable to Century Casinos, Inc. shareholders for the year ended December 31, 2025, was $61.416 million, compared to a net loss of $153.601 million in 2024[19] - Adjusted EBITDAR for the year ended December 31, 2025, was $105,377 thousand, reflecting an increase from $102,678 thousand in 2024[33] - Interest expense for the year ended December 31, 2025, totaled $104,783 thousand, slightly higher than $103,367 thousand in 2024[34] - Non-cash stock-based compensation for the year ended December 31, 2025, was $1,128 thousand, up from $66 thousand in 2024[28] Segment Performance - The US Midwest segment showed a 2% increase in net operating revenue for Q4 2025, while the US West segment experienced a 7% decrease[9] - Earnings from operations in the US East segment improved significantly, with a 108% increase in Q4 2025 compared to Q4 2024[10] - The US East segment reported a net operating revenue of $169,496 thousand for 2025, with an adjusted EBITDAR margin of 16%[33] - The US Midwest segment achieved a net operating revenue of $163,810 thousand in 2025, maintaining an adjusted EBITDAR margin of 36%[33] - The Canada segment's net operating revenue was $75,929 thousand for 2025, with a net earnings margin of 2%[33] - The Poland segment reported a net operating revenue of $84,168 thousand for 2025, with an adjusted EBITDAR margin of 4%[33] - The US West segment's net operating revenue decreased to $79,561 thousand in 2025, with a net earnings margin of (15%) compared to (70%) in 2024[33] Strategic Initiatives - The company opened a second casino in Wroclaw, Poland, in February 2026, indicating ongoing market expansion efforts[4] - The partnership with BetMGM, LLC for sports betting in Missouri began operations in December 2025, contributing to new revenue streams[4] - The company is exploring strategic alternatives, including the potential sale of its operations in Poland, to enhance portfolio performance[2] - The company is considering the potential sale of its Poland operations as part of a strategic review process[42] - Century Casinos is pursuing various projects in different stages of development, including the recently opened land-based casino and hotel in Caruthersville, Missouri[42] Financial Position - As of December 31, 2025, the Company had $68.9 million in cash and cash equivalents, down from $98.8 million at the end of 2024, primarily due to $22.3 million used in investing activities[16] - Total assets decreased to $1.147 billion as of December 31, 2025, from $1.200 billion at the end of 2024[20] - The Company had $337.7 million in outstanding debt as of December 31, 2025, a slight decrease from $339.6 million in 2024[16] - The Consolidated First Lien Net Leverage Ratio exceeded the required 5.50 to 1.00 as of December 31, 2025, although there were no outstanding revolving loans or letters of credit[16] Reporting and Compliance - The Company plans to post its Annual Report on Form 10-K for the year ended December 31, 2025, on its website once filed[17] - Century Casinos' common stock trades on The Nasdaq Capital Market under the symbol CNTY[41] - Management uses Adjusted EBITDAR margins as a measure to evaluate the efficiency of the company's casino operations[39] - The company defines net earnings margin as net earnings attributable to shareholders divided by net operating revenue, and Adjusted EBITDAR margin as Adjusted EBITDAR divided by net operating revenue[39] - Adjusted EBITDAR is not a direct alternative to net earnings and may not be comparable to similar measures used by other companies in the industry[38] Future Outlook - Future expectations include projections for Adjusted EBITDAR and cash flow in 2026, with potential risks and uncertainties affecting these forecasts[42]

Drug Approvals and Launches - TONMYA received FDA approval for the treatment of fibromyalgia in adults on August 15, 2025, and was launched on November 17, 2025[16]. - Tonix received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia, marking the first new treatment in over 15 years[70]. - The company launched TONMYA in the U.S. on November 17, 2025, which addresses core symptoms of fibromyalgia including pain, disturbed sleep, and fatigue[70]. Clinical Development Pipeline - The company has a diversified pipeline with multiple programs in clinical and preclinical development, including TNX-102 SL for major depressive disorder, which is expected to enter Phase 2 in mid-2026[19]. - TNX-1500, aimed at preventing kidney transplant rejection, is Phase 2-ready with a study expected to start in mid-2026[20]. - The company plans to initiate a Phase 2 study for TNX-2900, targeting Prader-Willi syndrome, in Q1 2027[21]. - TNX-1300, for cocaine intoxication, is currently in Phase 2 and has received Breakthrough Therapy designation from the FDA[20]. - TNX-1900 is being developed for binge eating disorder, adolescent obesity, and other CNS disorders through investigator-initiated studies at Massachusetts General Hospital[36]. - TNX-4800, a long-acting monoclonal antibody for Lyme disease, showed 95% effectiveness in preventing infection after 6 days of exposure to infected ticks; plans for Phase 2 studies are set for 2026 and 2028[39][40]. - TNX-2900, for Prader-Willi syndrome, received Orphan-Drug Designation and IND clearance in late 2023, with a Phase 2 study planned to begin in Q1 2027[48][49]. - TNX-102 SL is expected to enter Phase 2 for MDD in mid-2026, with a pivotal study enrolling approximately 360 patients across 30 U.S. sites[86]. - The OASIS trial, funded by a $3 million DoD grant, aims to investigate TNX-102 SL's efficacy in reducing adverse effects of acute trauma[88]. Market Strategy and Commercialization - The company aims to commercialize TONMYA for fibromyalgia, launched in November 2025, with approximately 90 U.S. sales representatives promoting it to healthcare providers[52]. - The company has established commercial operations and is focused on expanding TONMYA's market presence through lifecycle management strategies[27]. - The commercialization strategy for TONMYA includes a targeted sales approach with approximately 90 field sales representatives as of December 31, 2025[138]. - Tonix has implemented a market access strategy to support patient access to TONMYA across key payer segments, including commercial plans and government programs[141]. Intellectual Property and Patent Strategy - Tonix is pursuing a broad intellectual property strategy to protect its product candidates, including patents for TONMYA's composition and methods of use[55]. - The patent portfolio includes 45 issued U.S. patents and 46 issued non-U.S. patents as of March 5, 2026, with additional applications in progress[160]. - The company is actively pursuing 22 U.S. non-provisional patent applications and 238 non-U.S./non-PCT patent applications to strengthen its intellectual property position[160]. - TNX-102 SL has received U.S. market exclusivity for PTSD treatment until 2030, based on U.S. Patent No. 9,918,948[172]. - TNX-102 SL has European market exclusivity for depression treatment until March 2032, as per European patent 2,683,245[180]. Competitive Landscape - The U.S. fibromyalgia market has seen the introduction of TONMYA, the first new treatment in over 15 years, approved in August 2025, targeting non-restorative sleep[145]. - As of 2026, the U.S. fibromyalgia therapeutic landscape includes four FDA-approved treatments, with the first three being pregabalin, duloxetine, and milnacipran, which have been the standard of care since 2007-2009[145]. - Axsome Therapeutics initiated a Phase 3 trial of AXS-14 for fibromyalgia management in January 2026, indicating ongoing competition in the sector[146]. - The competitive landscape for migraine treatments has expanded with the FDA approval of Axsome Therapeutics' Symbravo and Satsuma Pharmaceuticals' Atzumi in 2025, highlighting increased innovation[148]. Research and Development Facilities - The company operates a 48,000 square foot RDC in Frederick, Maryland, and a 45,000 square foot ADC in Dartmouth, Massachusetts, for research and manufacturing of vaccines and biologics[50]. - The Advanced Development Center in Dartmouth, MA, is equipped for GMP production of live-virus vaccines and biologics, ready for reactivation by 2027 or in case of emergencies[132]. Specific Drug Developments - TNX-1300 is a recombinant protein enzyme that catalyzes the breakdown of cocaine, offering a targeted approach to cocaine intoxication management[102]. - TNX-801 is a potential smallpox and mpox vaccine with improved tolerability and efficacy compared to existing vaccines, requiring only a single dose for durable protection[121][122]. - TNX-4900, a selective S1R antagonist, has shown significant analgesic activity in preclinical models, with a Ki of 7.5 nM and oral bioavailability of approximately 28%[129]. - TNX-1700 has shown efficacy in preclinical studies for gastric and colorectal cancers, demonstrating tumor reduction and increased survival rates[116].

Competition and Market Dynamics - The company operates in highly competitive industries, facing significant competition from larger firms and new entrants, particularly in the semiconductor sector[76]. - The growth of the company's business is primarily dependent on the semiconductor and electronics systems industries, which are cyclical and subject to rapid technological changes[87]. - Increased customer consolidation may lead to reduced demand for the company's software solutions and services, impacting financial performance[90]. - The company's success depends on the interoperability of its software solutions with customers' intended use cases and competitors' products, which is critical for maintaining market share[92]. Financial Performance and Revenue Recognition - The company reported a significant fluctuation in revenue recognition, with a notable purchase order of approximately $5.0 million delayed from Q3 2024 to Q4 2024, impacting revenue recognition[81]. - The company must sustain or grow its software license revenue and maintenance/service revenue; failure to do so could negatively affect operational results[89]. - The company is subject to fluctuations in operating results, making historical performance unreliable as an indicator of future results[86]. - Variations in actual sales activity from forecasts could adversely affect the company's financial condition and results of operations, potentially leading to stock price decreases[120]. International Operations and Risks - 63% of the company's revenue for the years ended December 31, 2025 and 2024 was derived from international customers[98]. - Revenue from customers in China accounted for 20% and 18% of total revenue for the years ended December 31, 2025 and 2024, respectively[105]. - The U.S. government has implemented export controls affecting China, which may impact the company's ability to license or support software in that market[106]. - Political instability and geopolitical tensions, particularly between the U.S. and China, could negatively impact customer demand and operational results[99]. - The company faces risks from foreign exchange rate fluctuations that could adversely impact revenue, expenses, and cash flows[104]. Operational Challenges and Management - The company has experienced material weaknesses in internal controls over financial reporting, which could impair its ability to report financial conditions accurately[78]. - The company may need to invest more in research and development than anticipated, which could increase operating expenses and negatively affect results[95]. - The company has conducted recent headcount reductions to align with operational needs, which may temporarily impact productivity and sales metrics in future quarters[118]. - The company is highly dependent on senior management and key employees, and recent leadership transitions could disrupt operations and affect stock price[124]. Legal and Compliance Risks - The company faces risks related to cybersecurity threats that could compromise sensitive information and harm its reputation[71]. - The company is subject to various data privacy laws, and non-compliance could result in significant legal costs and damage to its business[152]. - The company is subject to various anti-corruption and anti-money laundering laws, with potential non-compliance leading to severe penalties and reputational harm[162]. - Between August 2019 and June 2022, the company filed voluntary disclosures regarding potential violations of U.S. export control laws, which could lead to enforcement actions and penalties[164]. Intellectual Property and Technology - Intellectual property litigation poses significant risks, potentially leading to substantial expenses and management distractions[137]. - The company may face challenges in protecting its proprietary technology, which could result in lost revenue and harm its competitive position[128]. - The integration of third-party open source software in the company's products poses risks of litigation and could require public release of proprietary source code[143]. - The company relies on trade secrets to protect its proprietary technology, and any unauthorized disclosure could materially affect its competitive position[142]. Economic and Market Conditions - The current macroeconomic environment is characterized by sustained global inflationary pressures and elevated interest rates, which may negatively impact the company's operating results[195]. - If economic conditions deteriorate, demand for products that the company's solutions help create could decline, leading to reduced sales and lower average selling prices[196]. - Uncertain macroeconomic conditions could adversely affect the banking and financial services industry, limiting the company's ability to obtain external financing[197]. Corporate Governance and Ownership - The company qualifies as a "controlled company," which allows it to rely on exemptions from certain corporate governance requirements, potentially affecting shareholder protections[156]. - The Pesic Family holds at least 25% of the voting power, requiring their approval for significant corporate actions, including amendments to the certificate of incorporation and mergers[158]. - The concentration of ownership by the Pesic Family may impede favorable changes in control or mergers that other stockholders might support[159]. - The company has the ability to designate board nominees based on ownership levels, which could influence corporate governance[158]. Future Outlook and Strategic Considerations - The company may require additional capital to respond to business opportunities, challenges, or unforeseen circumstances, which could limit growth[116]. - Future acquisitions may involve risks such as difficulties in incorporating acquired technologies and potential disruptions to ongoing business operations[122]. - The company does not intend to pay dividends for the foreseeable future, as it plans to retain earnings for business development and expansion[187]. - The company is classified as an "emerging growth company" and intends to take advantage of certain exemptions from public company reporting requirements, which may affect the attractiveness of its common stock to investors[198].

Financial Performance - FY'25 total revenue increased 16% year-over-year to $469.5 million, driven by electric sales of $310.7 million (+19% YoY) and coal sales of $148.7 million (+8% YoY) [1] - Net income for FY'25 increased to $41.9 million, with Adjusted EBITDA up approximately 3x year-over-year to $56.0 million [2] - Total sales and operating revenues increased to $469,466 thousand in 2025, up 16.2% from $404,159 thousand in 2024 [16] - Net income for 2025 was $41,871 thousand, a significant recovery from a net loss of $226,138 thousand in 2024 [16] - Electric sales rose to $310,737 thousand, representing a 19% increase from $261,527 thousand in the previous year [16] - The company reported a basic net income per share of $0.98 in 2025, compared to a loss of $5.72 per share in 2024 [16] Cash Flow and Liquidity - FY'25 operating cash flow rose 23% year-over-year to $81.1 million, supported by improved earnings and cash proceeds from prepaid forward power sales contracts [2] - Total liquidity was $38.8 million at December 31, 2025, consisting of $28.8 million of additional borrowing capacity and cash [2] - The company generated net cash provided by operating activities of $81,134 thousand in 2025, up from $65,934 thousand in 2024, an increase of 23.1% [18] Debt and Liabilities - Total bank debt decreased to $30.0 million at December 31, 2025, down from $44.0 million at September 30, 2025 [2] - Total liabilities decreased to $248,220 thousand in 2025, down 6.3% from $264,835 thousand in 2024 [14] Capital Expenditures - Capital expenditures for FY'25 totaled $69.2 million, including a ~$14 million deposit for the ERAS expansion at Merom [2] - Capital expenditures for 2025 were $69,215 thousand, an increase from $53,367 thousand in 2024, reflecting a growth of 29.7% [18] Assets - Total current assets increased to $123,387 thousand in 2025, up from $104,858 thousand in 2024, reflecting a growth of 17.6% [14] - Cash and cash equivalents at year-end rose to $10,070 thousand, compared to $7,232 thousand in 2024, marking an increase of 39.5% [18] Strategic Developments - Hallador's ERAS application for a 515 MW natural gas generation expansion was accepted, potentially increasing power generation capabilities by nearly 50% [2] - Hallador closed a new $120 million 3-year senior secured credit facility in March 2026, maturing in 2029 [5] - The company added two new board members with extensive experience in energy management and asset acquisitions to support growth plans [2]

Loan Portfolio Composition - As of December 31, 2025, commercial real estate and multi-family loans represent $691.2 million, or 42.5% of the total loan portfolio[251] - The construction and land loans decreased by $16.8 million, or 21.6%, to $61.3 million, which is 3.8% of the total loan portfolio at December 31, 2025[255] - As of December 31, 2025, the total loan portfolio includes $461.8 million, or 28.4%, in one-to-four family mortgage loans and home equity loans secured by residential properties[259] - The company had $130.3 million, or 8.0%, in commercial business loans as of December 31, 2025, which are primarily supported by borrower cash flows[262] Credit Quality and Risks - At December 31, 2025, there were $9.8 million of nonperforming commercial real estate loans in the portfolio[253] - Nonperforming assets were reported at $24.0 million, or 1.1% of total assets, indicating potential credit quality issues[267] - The allowance for credit losses on loans may be insufficient, necessitating additional provisions that could materially decrease net income[265] - The company is exposed to risks from construction and land development lending, which involves higher loan principal amounts and concentrated relationships with a small number of builders[256] - Environmental liabilities could arise from properties securing loans, potentially leading to significant remediation costs and reduced property values[261] Economic and Competitive Environment - A significant portion of loans is concentrated in Washington, making the company vulnerable to regional economic downturns[235] - Competition for deposits is strong, particularly from internet-based banking institutions, which may limit the company's ability to grow[241] - The financial services industry is highly competitive, with many competitors having greater resources for technological advancements[248] - The company faces risks associated with public health crises and geopolitical developments that could disrupt operations and negatively impact financial results[245] Interest Rate and Market Risks - Fluctuations in market value and interest rates could negatively impact the securities portfolio, leading to potential realized and unrealized losses[268] - A sustained increase in market interest rates could adversely affect earnings, particularly if the interest rates on deposits rise faster than those on loans, potentially reducing net interest income[280] - Changes in interest rates could negatively impact the fair value of fixed-rate securities, affecting shareholders' equity due to unrealized gains and losses[281] Regulatory and Compliance Issues - The company is subject to extensive fair lending laws, and non-compliance could result in sanctions that adversely impact business operations[304] - Regulatory compliance costs may increase due to evolving laws and regulations, impacting financial condition and operational results[300] - Changes in federal policy and regulations could lead to increased operating and compliance costs, affecting overall business prospects[301] Operational and Management Risks - The company relies on third-party servicers for a portion of its loan portfolio, which may limit its ability to foreclose on or repossess loans, increasing potential losses[291] - The effectiveness of the company's enterprise risk management program may be limited, potentially leading to unexpected losses and reputational damage[283] - The company faces operational risks from employee misconduct and fraud, which could result in financial losses and reputational harm despite substantial resources devoted to prevention[296] - The departure of key management personnel, including the former CEO and other executives, poses risks to the company's business and financial condition[305] Strategic Initiatives and Future Outlook - The company has opened four new full-service branches and three business centers over the past eight years, with plans for further expansion[306] - The company may expand its digital footprint through technology investments, which carry risks of failure and potential loss of investment[307] - The company has made minority investments in fintech and specialty finance companies, which may pose risks of financial difficulties and reputational damage[269] Financial Performance and Market Position - The stock price fluctuated between $6.96 and $11.88 during the year ended December 31, 2025, indicating potential volatility[309] - The company has not declared cash dividends on its common stock since May 2025 as part of a prudent capital management approach, which could affect the market price of its common stock[293] - As of December 31, 2025, First Northwest and First Fed met the minimum capital ratio requirements and exceeded the capital conservation buffer requirement, which is crucial for maintaining financial stability[292]

Regulatory Compliance - The company is subject to extensive federal, state, and local regulations impacting its electric power generation and coal mining operations, including health and safety, environmental standards, and mine permits[22]. - Compliance with environmental laws has significantly increased operating costs, with the company expecting these costs to continue to rise due to evolving regulations[30]. - The permitting process for electric power generation can take several years and may be subject to administrative and judicial challenges, potentially delaying operations[34]. - The company is required to maintain bonds to secure obligations for land reclamation and other regulatory requirements, with increasing difficulty in securing new surety bonds[45]. - The company is committed to compliance with applicable laws and regulations, with significant costs associated with maintaining compliance expected to continue[30]. - The company has been cited for violations in the ordinary course of business but has not faced substantial fines or penalties that would materially affect operations[38]. - The company is subject to various environmental regulations, including the CCR rule, which could materially impact its operations and financial condition[77]. - Legal challenges to emissions regulations create uncertainty regarding compliance costs and operational impacts on coal mining and power generation[56]. Environmental Regulations - Compliance with the Clean Air Act and related regulations imposes significant operational costs and affects coal mining and electric power generation operations[50]. - The EPA's Acid Rain Program and Cross-State Air Pollution Rule require emissions allowances and could lead to increased operational costs for coal-fired power plants[53]. - The Mercury and Air Toxic Standards mandate capital investments for retrofitting power plants, potentially decreasing future demand for coal[53]. - The 2024 EPA ELG Rule establishes more stringent requirements for wastewater discharge from power plants, with compliance deadlines extended by five years due to legal challenges[69]. - Future GHG emissions regulations could increase costs for fossil fuel production and consumption, adversely affecting demand for coal[62]. - The Clean Water Act imposes strict controls on pollutant discharges, which may increase operational costs and affect strategic planning[63]. - The EPA's regional haze program may restrict new coal-fired power plant construction and impose additional control measures on existing plants[59]. - The definition of "waters of the United States" under the Clean Water Act has been amended, potentially impacting future permitting requirements[64]. Financial Performance - The company reported estimated revenue from forward sales of $1.3 billion as of December 31, 2025[271]. - Segment operating revenues from electric operations increased by $49.2 million, or 18.8%, compared to 2024, driven by a 23.7% increase in incremental energy sales[281]. - The average contracted price per MWh for 2026 is $43.32, with total contracted revenue from power expected to be $543.47 million[272]. - The company generated 4.696 million MWh in 2025, an increase from 3.830 million MWh in 2024[278]. - Contracted coal revenue from third parties is expected to total $323.47 million, with an average price per ton of $55.72 for 2026[272]. - The segment EBITDA for electric operations increased to $85.43 million in 2025 from $72.01 million in 2024[276]. - Other operating revenue increased by $2.6 million, or 273.6%, compared to 2024 due to exclusivity payments received during contractual negotiations[282]. - Total revenue for 2025 reached $469.466 million, with electric sales contributing $310.737 million and coal sales $148.655 million[301]. Operational Costs - Fuel costs increased by $20.8 million, or 18.6%, on a segment basis and $15.3 million, or 33.0%, on a consolidated basis, attributed to a 22.6% increase in electricity generation[283]. - Cost of purchased power rose by $10.0 million, or 91.9%, from 2024, with approximately 47.0% of net hourly purchases occurring in the fourth quarter due to equipment issues[284]. - Segment operating revenue from coal operations increased by $18.5 million, or 9.1%, despite only mining Oaktown Mine No. 1, with total tons sold rising by 0.4 million tons, or 11.6%[290]. - Operating expenses totaled $408.410 million in 2025, with significant costs in labor ($110.678 million) and other operating costs ($129.246 million)[301]. Capital Expenditures and Debt - Capital expenditures for coal operations totaled $25.4 million in 2025, with a capex per ton sold of $5.88[297]. - For the year ended December 31, 2025, capital expenditures (Capex) totaled $69.2 million, with allocations of $25.4 million to Oaktown, $25.5 million to Merom, $4.7 million to Merom – ELG, and $13.6 million to the ERAS Project[313]. - The company expects a modest increase in capital expenditures for 2026 compared to 2025, excluding impacts from the ERAS project[313]. - As of December 31, 2025, bank debt stood at $30.0 million, which was repaid after year-end[316]. - A new credit agreement was entered into on March 5, 2026, with a $75.0 million revolving credit facility and a $45.0 million delayed draw term loan, maturing on March 5, 2029[319]. - The new credit facility bears interest margins ranging from 2.25% to 3.75% above SOFR, with a commitment fee of 0.50% on unused portions[319]. - The company aims to maintain debt levels that provide equity returns without undue risk, relying on Adjusted EBITDA to service or refinance debt[315]. Employment and Production - As of December 31, 2025, the company employed 633 full-time employees and temporary miners, with 599 directly involved in coal mining or washing[101]. - The company has established long-term relationships with key suppliers, although it is primarily dependent on one supplier for underground mining equipment[85]. - The company is committed to supplying a base amount of 5.7 million tons of coal to third-party customers through 2028 and 7.8 million tons to Merom during the same period[97]. - Anticipated production pace for the mines is 3.7 million tons annually to meet market demand for Merom and third-party customers[98]. - 56% of the company's 2025 sales, excluding Merom, were derived from locations in the State of Indiana[97]. Income and Loss - Net income for 2025 was $41.871 million, translating to a diluted earnings per share of $0.96[301]. - Income before income taxes increased by $274.6 million, or 100.2%, from a loss of $274.1 million in 2024 to income of $0.5 million in 2025[295]. - The company experienced a loss before income taxes of $43.704 million in 2025, with significant losses attributed to interest expenses and equity method investment losses[301]. - The company reported a net loss of $226.138 million for 2024, with a diluted loss per share of $5.72[302].

Financial Overview - The company completed its Initial Public Offering (IPO) on April 3, 2025, raising gross proceeds of $230 million from the sale of 23 million Public Units at $10.00 each [21]. - An additional $6 million was generated from the private sale of 600,000 Private Placement Units, bringing total gross proceeds to $236 million [22]. - The total amount of $230 million from the IPO and Private Placement was placed in a Trust Account [23]. - As of December 31, 2025, the company has $237,007,209 available for a Business Combination, excluding redemptions and taxes [61]. - The company has approximately $805,124 in proceeds held outside the Trust Account as of December 31, 2025, to cover costs associated with potential liquidation [111]. - The Trust Account held marketable securities totaling $237,007,209, including approximately $7,007,209 of interest income [180]. - The company incurred fees of $15,554,267 during the Initial Public Offering, which included a cash underwriting fee of $4,000,000 and a Deferred Fee of $10,950,000 [178]. - The company has no long-term debt or capital lease obligations, with administrative service fees amounting to $133,000 for the year ended December 31, 2025 [187]. Business Combination Requirements - The company must complete its initial Business Combination by April 3, 2027, or face termination and distribution of Trust Account funds [24]. - The company aims to complete its initial Business Combination by April 3, 2027, with the possibility of seeking shareholder approval for extensions [45]. - The company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account [48]. - The company intends to structure its initial Business Combination to acquire 100% of the equity interests or assets of the target business, but may acquire less than 100% under certain conditions [49]. - If the aggregate cash consideration for all Public Shares validly submitted for redemption exceeds the available cash, the initial Business Combination will not be completed, and all submitted Public Shares will be returned [86]. - The company may seek additional financing through private offerings of debt or equity securities to complete its initial Business Combination, which could lead to significant dilution for Public Shareholders [62]. - The company targets businesses with enterprise values greater than the net proceeds from its Initial Public Offering and Private Placement, indicating a need for additional financing if cash requirements exceed available funds [62]. Management Team and Expertise - The Management Team has a track record of identifying over 130 target companies and engaging with 58 of them during previous efforts [27]. - The Management Team's past performance includes a successful Business Combination that led to the trading of Critical Metals Corp. on Nasdaq with a market capitalization of approximately $1.184 billion [27]. - The company is focusing on sectors such as restaurant, hospitality, food and beverage, and technology, leveraging the Management Team's expertise in these areas [20]. - The Management Team is expected to generate proprietary deal flow through its analysis and solicitations, providing a competitive advantage in identifying acquisition opportunities [28]. - Jamie Karson has extensive experience in analyzing operating performance and evaluating acquisition opportunities, contributing to shareholder equity growth at Steve Madden Ltd., which has a market cap of $3 billion [208]. - Daniel Lee has served as CFO and Head of Business Development, focusing on potential acquisitions and financings, and previously led corporate finance functions at RiskSpan, Inc. [209]. - Neil Leibman is the COO of the Texas Rangers Baseball Club and has experience in managing public and private companies, including Gexa Corp., which was sold to FPL Group, Inc. in June 2005 [210]. - Warren Thompson is the President and Chairman of Thompson Hospitality Corporation, which has been involved in food service and facilities management since 1992 [211]. - David Perlin has been a Senior Vice President at Shepherd Kaplan Krochuk LLC, managing $9 billion in assets, and previously served as CEO of Pearl Investment Partners [212]. - Nick Salis has over 15 years of experience in the restaurant industry and played a key role in scaling &pizza from 3 to 50 units in 4 years [216]. - Geovannie Concepcion led a digital transformation at Famous Dave's, resulting in positive same-store sales for six consecutive quarters, reversing a multiyear decline [218]. - Michael Kuchta co-founded Analytical Technologies Group, which was sold to a private equity group, generating significant returns for investors [217]. Shareholder Rights and Redemption - The company will provide public shareholders the opportunity to redeem shares upon completion of the initial Business Combination [44]. - Public Shareholders will have the opportunity to redeem their Public Shares either through a general meeting or a tender offer [87]. - A quorum for the shareholder meeting requires at least one-third of the issued and outstanding Ordinary Shares to be represented [90]. - To approve the initial Business Combination by Ordinary Resolution, approximately 32.89% of the 23,000,000 Public Shares, or 7,566,667 shares, must be voted in favor [90]. - If structured as a statutory merger, a Special Resolution requires 55.55% of the Public Shares, or 12,777,778 shares, to be voted in favor [91]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent [100]. - The transfer agent will charge approximately $100.00 for the process of delivering Public Shares for redemption [103]. - Funds for redeeming Public Shares will be distributed promptly after the completion of the initial Business Combination [104]. - The expected redemption price upon dissolution is approximately $10.30 per Public Share as of December 31, 2025, although actual amounts may be less due to creditor claims [112]. - The company has a liability to ensure that the Trust Account maintains at least $10.00 per Public Share, with potential claims from third parties posing a risk to this amount [115]. - If the Trust Account is reduced below $10.00 per Public Share due to creditor claims, shareholders may receive less than this amount upon redemption [116]. Risks and Challenges - The company may experience dilution due to the conversion of Founder Shares and Private Placement Rights into Class A Ordinary Shares upon consummation of the initial Business Combination [31]. - The management team may not have the necessary skills or experience to manage the target business post-acquisition, which could impact future performance [70]. - The lack of business diversification may pose risks, as success may depend entirely on the performance of a single business post-acquisition [69]. - The company faces competition from other SPACs, private equity groups, and public companies, which may limit its ability to acquire larger target businesses [121]. - The company may face significant challenges in maintaining control of a target business after the initial Business Combination, which could affect operations and profitability [141]. - The company may incur substantial debt to complete a Business Combination, adversely affecting its financial condition and shareholder value [137]. - The company is subject to regulatory review and approval requirements, which may delay or prohibit the completion of its initial Business Combination [141]. - The company may face conflicts of interest due to relationships between its management and potential target businesses [137]. - The company faces risks related to its status as a blank check company with no operating history and limited revenue, which may affect its ability to complete a Business Combination [133]. - The company may not be able to complete its initial Business Combination within the Combination Period, which could lead to liquidation and redemption of Public Shares [133]. - The company may face increased competition for attractive Business Combination targets, which could raise costs and complicate the completion of its initial Business Combination [133]. - The company may not hold an annual general meeting until after the consummation of its initial Business Combination, delaying shareholder discussions with management [136]. Corporate Governance and Compliance - The company is subject to reporting obligations under the Exchange Act, including filing annual, quarterly, and current reports with the SEC [123]. - The company qualifies as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements, including auditor attestation requirements [127][128]. - The company will remain an emerging growth company until it has total annual gross revenue of at least $1.235 billion or the market value of its Class A Ordinary Shares exceeds $700 million [130]. - The company is classified as a "smaller reporting company," allowing it to provide only two years of audited financial statements until certain revenue and market value thresholds are met [131]. - The company is considered a "controlled company" under Nasdaq corporate governance standards, which may allow it to qualify for exemptions from certain corporate governance requirements [136]. - The company is controlled by its Sponsor, which appoints all directors prior to the initial Business Combination, potentially influencing shareholder votes [137]. - The company has no family relationships among directors or executive officers, ensuring independent governance [214]. - There are no material legal proceedings involving any director or executive officer in the last ten years, indicating a clean legal standing [215]. - The company has not selected any specific target businesses for its initial Business Combination, leaving shareholders unable to assess the merits or risks of potential targets [137]. Operational and Financial Performance - For the year ended December 31, 2025, the company reported a net income of $6,469,756, primarily from interest income of $7,007,209 on marketable securities held in the Trust Account [177]. - The company incurred operating costs of $537,453 for the same period, which partially offset the interest income [177]. - The company has not paid any cash dividends to date and does not intend to do so prior to the completion of its initial Business Combination [159]. - The company has not encountered any cybersecurity incidents since its Initial Public Offering, but remains vulnerable to such risks [151]. - The company may continue to seek a Business Combination with a different target if the initial one is not completed within the Combination Period [106]. - The company is required to evaluate its internal control procedures for the fiscal year ending December 31, 2026, as mandated by the Sarbanes-Oxley Act [125]. - The company has a liquidity risk mitigation strategy that may involve liquidating investments held in the Trust Account [181]. - The company has no critical accounting estimates to disclose as of December 31, 2025 [194].

Financial Performance - Revenue for the years ended December 31, 2025 and 2024 was approximately $7.2 million and $8.0 million, respectively, indicating a decline in revenue [43]. - Net losses for the years ended December 31, 2025 and 2024 were $896,333 and $3,759,238, respectively, with an accumulated deficit of $9,720,526 as of December 31, 2025 [43][44]. - Cash reserves as of December 31, 2025 and 2024 were $1,614,733 and $2,395,405, respectively, indicating a decrease in liquidity [44]. Going Concern and Risks - The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses [47]. - The company faces significant competition in the healthcare services market, which may adversely affect its financial condition and results of operations [48]. - The company is exposed to risks from government contracting, including potential audits and investigations that could result in civil and criminal penalties [80]. Customer and Market Dynamics - Retaining existing customers and attracting new ones is critical for success, with potential impacts from pricing pressures and changing business models [50]. - The sales cycle for the company's products is lengthy, particularly with large healthcare organizations, which may lead to revenue decreases if clients delay purchasing decisions [70]. - The healthcare staffing market is competitive, and the company must effectively recruit and retain qualified healthcare professionals to maintain service quality and profitability [76]. Regulatory and Compliance Issues - The company is subject to extensive federal and state healthcare industry regulations, which can indirectly affect demand and pricing for its services [97]. - Legal and regulatory proceedings could result in unexpected adverse outcomes, impacting the company's operations and financial results [82]. - Government contracts are subject to more onerous terms and conditions, which can involve additional costs and risks compared to commercial contracts [84]. Technology and Data Security - Disruptions in service or data system failures could materially impact the company's business and financial condition [60]. - Breaches and failures of IT systems expose the company to potential liability and reputational harm, affecting its operations [61]. - The company faces significant risks related to unauthorized access to data and potential breaches, which could lead to substantial financial costs and reputational damage [62]. Customer Concentration - FSSA accounted for approximately 35% and 61% of the company's revenues and accounts receivable for the years ended December 31, 2025 and 2024, respectively [96]. - Humana, Inc. represented about 37% and 74% of the company's revenue and accounts receivable for the year ended December 31, 2025 [96]. - The company relies on a small number of large customers, and the loss of one or more major customers could materially affect its financial condition and results [96]. Market and Stock Considerations - The company's common stock is currently traded on the OTC QB Market, which may negatively impact stock price and liquidity due to lower financial standards compared to major exchanges [100]. - The market price of Class A common stock may be highly volatile, influenced by factors such as failure to develop digital health platforms and changes in healthcare practices [103]. - The dual-class structure may lead to exclusion from certain stock indices, adversely affecting the attractiveness of Class A common stock to investors [113]. Corporate Governance and Shareholder Rights - The concentration of voting power in Class B common stockholders may limit the influence of Class A stockholders on corporate matters, potentially affecting stock price [108]. - Anti-takeover provisions in the company's governance documents may impair potential acquisition attempts [117]. - The exclusive forum provision designates the Court of Chancery of Delaware for certain disputes, potentially limiting stockholders' judicial options [122]. Emerging Growth Company Status - The company is classified as an "emerging growth company," allowing it to benefit from reduced reporting requirements until it meets specific revenue or market value thresholds [130]. - The company may delay adopting new accounting standards under the JOBS Act, which could affect its financial reporting [131]. - The market value of Class A common stock held by non-affiliates must exceed $700 million to cease being classified as an emerging growth company [130].

Sales and Revenue - Walmart accounted for 17%, 19%, and 21% of consolidated net sales for the years ended December 31, 2025, 2024, and 2023, respectively[41] - Sales to Amazon represented 12%, 13%, and 11% of consolidated net sales for the years ended December 31, 2025, 2024, and 2023, respectively[41] - The Company’s net sales for the third and fourth quarters accounted for 58% of total annual net sales in 2025[59] - For the year ended December 31, 2025, approximately 8% of the Company's net sales revenue was in foreign currencies, compared to 7% for the year ended December 31, 2024[277] Operations and Facilities - The Company operates distribution facilities totaling approximately 1,855,600 square feet across various locations, including Rialto, California (703,000 sq ft) and Robbinsville, New Jersey (700,000 sq ft)[42] - The Company has a presence in international markets through subsidiaries in the U.K., Europe, China, and the Asia Pacific region[33][34] - The Company actively sources products from a diverse global network, including countries such as China, Vietnam, and India[47] Supply Chain and Sourcing - The Company sources almost all of its products from suppliers located outside the United States, primarily in China[35] - The Company’s reliance on international suppliers exposes it to various risks, including political and economic instability[21] Financial Position and Debt - The Company has substantial indebtedness, which may impact its financial position and cash flows[19] - As of December 31, 2025, approximately $139.1 million of the Company's debt carries a variable rate of interest, an increase from $110.2 million at December 31, 2024[280] - A hypothetical 10% change in exchange rates would result in an increase of approximately $2.0 million in SG&A expenses[277] - The Company has foreign exchange contracts with an aggregate gross notional value of $8.0 million as of December 31, 2024, which was zero by December 31, 2025[278] - The Company entered into interest rate swap agreements with an aggregate notional value of $50.0 million to manage interest rate exposure[279] Product Categories - The Company’s product categories include Kitchenware, Tableware, and Home Solutions, targeting moderately priced consumer products[30][31] Human Resources - The Company had approximately 1,080 full-time employees as of December 31, 2025, with 58% located in the United States and Puerto Rico[52] - The Company’s executives and key employees are critical to its success, and their loss could adversely affect the business[28] Intellectual Property - The Company holds approximately 1,060 design and utility patents, which it believes will not materially affect its segments upon expiration[50] Regulatory Compliance - The Company’s spice filling operation is regulated by the U.S. Food and Drug Administration[56]